Septerna (NASDAQ:SEPN) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Septerna (NASDAQ:SEPN) released its earnings results on Thursday. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05, Zacks reports. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million.

Septerna Stock Performance

NASDAQ:SEPN traded down $0.19 during mid-day trading on Friday, hitting $6.10. 214,364 shares of the company traded hands, compared to its average volume of 462,764. Septerna has a one year low of $4.17 and a one year high of $28.99. The company has a fifty day moving average of $10.17.

Insider Buying and Selling

In other Septerna news, Director Alan Ezekowitz purchased 41,355 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were acquired at an average cost of $6.00 per share, with a total value of $248,130.00. Following the completion of the acquisition, the director now directly owns 104,101 shares in the company, valued at $624,606. The trade was a 65.91 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Gil M. Labrucherie acquired 10,500 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was acquired at an average cost of $5.51 per share, with a total value of $57,855.00. Following the purchase, the chief financial officer now owns 10,500 shares of the company’s stock, valued at approximately $57,855. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 74,346 shares of company stock valued at $439,670.

Analyst Upgrades and Downgrades

SEPN has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 price target on shares of Septerna in a research report on Tuesday, February 11th. Wells Fargo & Company dropped their target price on shares of Septerna from $14.00 to $11.00 and set an “equal weight” rating on the stock in a report on Friday.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.